Early Percutaneous Coronary Intervention, Platelet Inhibition With Eptifibatide, and Clinical Outcomes in Patients With Acute Coronary Syndromes

Abstract

Background—Platelet glycoprotein (GP) IIb/IIIa antagonists prevent the composite end point of death or myocardial infarction (MI) in patients with acute coronary syndromes. There is uncertainty about whether this effect is confined to patients who have percutaneous coronary interventions (PCIs) and whether PCIs further prevent death or MI in patients… (More)

Topics

11 Figures and Tables

Cite this paper

@inproceedings{Kleiman2000EarlyPC, title={Early Percutaneous Coronary Intervention, Platelet Inhibition With Eptifibatide, and Clinical Outcomes in Patients With Acute Coronary Syndromes}, author={Neal S. Kleiman and Greg C. Flaker and Karen S. Pieper and Lisa G. Berdan and Dennis Vassilios Cokkinos and Maarten L. Simoons and Eric J. Topol and Robert A. Harrington}, year={2000} }